| Identification | Back Directory | [Name]
Ziprasidone mesilate | [CAS]
199191-69-0 | [Synonyms]
ziprasidone mesilate
ZIPRASIDONE MESYLATE
Ziprasidone mesylate trihydrate
Ziprasidone mesilate trihydrate CRS
Ziprasidone Hcl / Mesilate 138982-67-9 /
5-[2-[4-(1,2-benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one mesilate
2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-,monomethanesulfonate, trihydrate
2H-INDOL-2-ONE, 5-[2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]ETHYL]-6-CHLORO-1,3-DIHYDRO-, MONOMETHANESULFONATE, TRIHYDRATE | [Molecular Formula]
C22H31ClN4O7S2 | [MDL Number]
MFCD07363968 | [MOL File]
199191-69-0.mol | [Molecular Weight]
563.09 |
| Hazard Information | Back Directory | [Uses]
Antipsychotic (central D2and 5HT2receptor antagonist). | [Definition]
ChEBI: The methanesulfonate trihydrate salt of ziprasidone. | [Brand name]
Geodon (Pfizer). | [in vivo]
Ziprasidone mesylate trihydrate (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold[3]. | Animal Model: | Eight-week-old female Sprague-Dawley rats weighing 200 to 250 g[3] | | Dosage: | 20 mg/kg | | Administration: | Oral gavage; 20 mg/kg; once daily; 7 weeks | | Result: | Gained significantly less weight (P = 0.031), had a lower level of physical activity (P = 0.016), showed a higher resting energy expenditure (P < 0.001), and displayed a greater capacity for thermogenesis when subjected to cold (P < 0.001). |
| [IC 50]
Rat 5-HT2 Receptor: 0.42 nM (Ki); Rat 5-HT1A Receptor: 3.4 nM (Ki); Rat D2 Receptor: 4.8 nM (Ki) |
|
|